Comprehensive Review Maps ctDNA Treatment Monitoring Across Lung, Colorectal, and Breast Cancer
This review provides an up-to-date synthesis of ctDNA as a dynamic biomarker for monitoring treatment response across lung, colorectal, and breast cancers. The authors detail how ctDNA informs treatment selection, tracks therapeutic response in real time, and identifies emerging drug resistance. Current technical challenges and future directions for integrating ctDNA monitoring into routine precision oncology workflows are discussed.
The original study
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology.
- Authors
- Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al.
- Journal
- NPJ precision oncology
- Type
- Journal Article, Review
- PMID
- 40122951
Original abstract
Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, as evidenced by its increasing integration into clinical practice. Carrying tumor specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide a comprehensive, up-to-date summary of ctDNA in monitoring treatment response with a focus on lung, colorectal, and breast cancers, and discuss current challenges and future directions.